Actelion (Actelion) Net Change in Cash : $284 Mil (TTM As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Actelion's Net Change in Cash for the three months ended in Mar. 2017 was $264 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2017 was $284 Mil.

Actelion Net Change in Cash Historical Data

The historical data trend for Actelion's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Net Change in Cash Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Net Change in Cash

Get a 7-Day Free Trial

-280.87

-441.77

591.94

-804.01

88.77

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Net Change in Cash	Get a 7-Day Free Trial															67.99	-54.87	-7.91	83.06	264.00

Actelion Net Change in Cash Calculation

Actelion's Net Change in Cash for the fiscal year that ended in Dec. 2016 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	902.031	+	-60.507	+	-752.521	+	-0.236
	=	89

Actelion's Net Change in Cash for the quarter that ended in Mar. 2017

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 202.066 + -9.135 + 71.074 + -0.005

= 264

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $284 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actelion Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Actelion's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Net Change in Cash

Comparable Companies

ALXN XKRX:207940 SGEN REGN INCY XKRX:068270 HKSE:01177 XBRU:UCB OCSE:GMAB HKSE:02269 BMRN HKSE:06160 XAMS:GLPG ALNY ARRY NBIX SZSE:300122 IONS JAZZ TECH

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary
By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track
By reports.droy reports.droy • 02-18-2015

Jean Hynes Reduces Stake in Actelion
By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary
By Holly LaFon Holly LaFon • 02-14-2017